This blend is not an FDA-approved product, and there are no dedicated safety trials of the pairing. This page summarises how its potential risks are discussed and does not constitute medical advice.
Overview
Because the blend raises growth hormone and IGF-1 through two pathways, its side effect profile combines GH-related effects with the individual profiles of tesamorelin and ipamorelin. Dedicated safety data for the combination are limited, so discussion is framed around the components and shared GH biology.
Component-level considerations
The two peptides also carry their own considerations:
- Tesamorelin — injection-site reactions and effects observed in its studied population.
- Ipamorelin — noted for relatively little effect on prolactin and cortisol compared with less selective secretagogues.
How these profiles interact when combined has not been formally characterized.
General safety themes
The usual peptide caveats apply:
- Local reactions at injection sites.
- Headache, flushing, or lightheadedness.
- Uncertainty about interactions, especially with other hormonal agents.
- Product quality and purity risks with unregulated sourcing of blends.
Context and caveats
Sustained elevation of GH and IGF-1 carries theoretical risks that are better characterized for recombinant growth hormone than for secretagogue blends. The absence of dedicated combination trials means the true risk profile of the pairing remains incompletely defined, and any use should involve qualified clinical supervision.